Biomarin Pharmaceutical

Uproar over suddenly hiked-up medications may not crush health care stocks for long, but it does force the industry to justify value.
Jason Karp’s still-young hedge fund firm generates big numbers with an unusual long-short strategy — and a CIA interrogator.